---
title: "Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295398593.md"
description: "Passage BIO reported a Q2 2026 net loss of $7.82M, an improvement from the prior year's $9.39M. The company is executing a merger with Remix and winding down AAV gene therapy programs. It completed a 75% workforce reduction and restructured its pipeline. Cash reserves stand at $24.2M, with continued operations dependent on the merger closing or additional financing."
datetime: "2026-08-10T11:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295398593.md)
  - [en](https://longbridge.com/en/news/295398593.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295398593.md)
generator: "portal-rs"
---

# Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary

Passage BIO, Inc. reported results for the quarter ended 2026, recording a comprehensive loss of ($7.82M) and a net loss of ($7.82M), with diluted loss per share of ($2.44) compared with a net loss of ($9.39M) and diluted loss per share of ($2.96) in the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($7.82M)

($9.39M)

16.7%

Net income²

($7.82M)

($9.39M)

16.7%

Diluted EPS³

($2.44)

($2.96)

17.6%

*¹ Reported as “Comprehensive loss”. ² Reported as “Net loss”. ³ Reported as “loss per share of common stock, basic and diluted”.*

**Business Highlights**

-   Strategic transaction: Executed a merger agreement with Remix on June 24, 2026; closing is expected in Q4 2026 subject to approvals and a concurrent $100M financing.
-   Program wind-down: Began winding down AAV gene therapy programs in Q2 2026, terminating key manufacturing, collaboration and license agreements with Catalent, Gemma and the University of Pennsylvania.
-   Operational restructuring: Completed approximately 75% workforce reduction under a Restructuring Plan, recording severance and materially reducing R&D and G&A headcount and expenses.
-   Pipeline transition: Outlicensed GM1, transferred Huntington’s disease and TLE research to Gemma, and initiated partial termination of PBFT02 license rights to Penn for FTD‑GRN.
-   Liquidity: Cash runway was constrained at $24.2M as of June 30, 2026; continued operations depend on the merger closing or additional financing.

Original SEC Filing: Passage BIO, Inc. \[ PASG \] - 10-Q - Aug. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PASG.US](https://longbridge.com/en/quote/PASG.US.md)

## Related News & Research

- [Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE](https://longbridge.com/en/news/297896887.md)
- [Passage Bio announces $70 million private placement at $1.39 per share, including pre-funded warrants](https://longbridge.com/en/news/297895358.md)
- [Alexandria Real Estate Equities declares Q3 2026 dividend of R$ 0.63 per unit](https://longbridge.com/en/news/297928934.md)
- [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**